{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:11:16Z","timestamp":1777871476146,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10928-024-09948-1","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:37:52Z","timestamp":1737052672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria"],"prefix":"10.1007","volume":"52","author":[{"given":"Lan","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artem","family":"Uvarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Peyret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie H.","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"3","key":"9948_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, Mehrotra D, Riley S, Sager P, Tornoe C, Wang Y (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45(3):383\u2013397. https:\/\/doi.org\/10.1007\/s10928-017-9558-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9948_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green CL, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu J, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stoltz RR, Zhou M, Stockbridge N (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 97(4):326\u2013335. https:\/\/doi.org\/10.1002\/cpt.60","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9948_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/anec.12128","volume":"19","author":"B Darpo","year":"2014","unstructured":"Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, Jarugula V, Johannesen L, Keirns J, Krudys K, Ortemann-Renon C, Riley S, Rogers-Subramaniam D, Stockbridge N (2014) The IQ-CSRC prospective clinical phase 1 study: can early QT assessment using exposure response analysis replace the thorough QT study? Ann Noninvasive Electrocardiol 19(1):70\u201381. https:\/\/doi.org\/10.1111\/anec.12128","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"9750","key":"9948_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria Lancet 376(9750):1417\u20131427. https:\/\/doi.org\/10.1016\/S0140-6736(10)60961-0","journal-title":"Phenylketonuria Lancet"},{"issue":"2","key":"9948_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","volume":"107","author":"A Hillert","year":"2020","unstructured":"Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, Chiesa AE, Christodoulou J, Dordevic M, Desviat LR, Eliyahu A, Evers RAF, Fajkusova L, Feillet F, Bonfim-Freitas PE, Gizewska M, Gundorova P, Karall D, Kneller K, Kutsev SI, Leuzzi V, Levy HL, Lichter-Konecki U, Muntau AC, Namour F, Oltarzewski M, Paras A, Perez B, Polak E, Polyakov AV, Porta F, Rohrbach M, Scholl-Burgi S, Specola N, Stojiljkovic M, Shen N, Santana-da Silva LC, Skouma A, van Spronsen F, Stoppioni V, Thony B, Trefz FK, Vockley J, Yu Y, Zschocke J, Hoffmann GF, Garbade SF, Blau N (2020) The Genetic Landscape and Epidemiology of Phenylketonuria. Am J Hum Genet 107(2):234\u2013250. https:\/\/doi.org\/10.1016\/j.ajhg.2020.06.006","journal-title":"Am J Hum Genet"},{"issue":"4","key":"9948_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ymgme.2019.02.001","volume":"126","author":"N Smith","year":"2019","unstructured":"Smith N, Longo N, Levert K, Hyland K, Blau N (2019) Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. Mol Genet Metab 126(4):406\u2013412. https:\/\/doi.org\/10.1016\/j.ymgme.2019.02.001","journal-title":"Mol Genet Metab"},{"issue":"4","key":"9948_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ymgme.2008.04.007","volume":"94","author":"K Sawabe","year":"2008","unstructured":"Sawabe K, Yamamoto K, Harada Y, Ohashi A, Sugawara Y, Matsuoka H, Hasegawa H (2008) Cellular uptake of sepiapterin and push-pull accumulation of tetrahydrobiopterin. Mol Genet Metab 94(4):410\u2013416. https:\/\/doi.org\/10.1016\/j.ymgme.2008.04.007","journal-title":"Mol Genet Metab"},{"issue":"3","key":"9948_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.febslet.2004.10.056","volume":"577","author":"B Thony","year":"2004","unstructured":"Thony B, Ding Z, Martinez A (2004) Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: implications for tetrahydrobiopterin-responsive hyperphenylalaninemia. FEBS Lett 577(3):507\u2013511. https:\/\/doi.org\/10.1016\/j.febslet.2004.10.056","journal-title":"FEBS Lett"},{"issue":"1","key":"9948_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.gimo.2023.100039","volume":"1","author":"S Gersting","year":"2023","unstructured":"Gersting S, Barroso M, Etzold S, Smith N (2023) The effects of the pharmacological chaperone sepiapterin on phenylalanine hydroxylase activity of Common variants in Phenylketonuria. Genet Med Open 1(1):17. https:\/\/doi.org\/10.1016\/j.gimo.2023.100039","journal-title":"Genet Med Open"},{"issue":"5","key":"9948_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cpdd.1363","volume":"13","author":"L Gao","year":"2024","unstructured":"Gao L, Kaushik D, Xia Y, Ingalls K, Milner S, Smith N, Kong R (2024) Relative oral bioavailability and food effects of two sepiapterin formulations in healthy participants. Clin Pharmacol Drug Dev 13(5):506\u2013516. https:\/\/doi.org\/10.1002\/cpdd.1363","journal-title":"Clin Pharmacol Drug Dev"},{"key":"9948_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-024-00488-0","author":"L Gao","year":"2024","unstructured":"Gao L, Kaushik D, Ingalls K, Milner S, Smith N, Kong R (2024) Clinical Assessment of breast Cancer resistance protein (BCRP)-Mediated drug-drug interactions of Sepiapterin with Curcumin and Rosuvastatin in healthy volunteers. Drugs R D. https:\/\/doi.org\/10.1007\/s40268-024-00488-0","journal-title":"Drugs R D"},{"key":"9948_CR12","doi-asserted-by":"publisher","first-page":"155116","DOI":"10.1016\/j.metabol.2021.155116","volume":"128","author":"D Bratkovic","year":"2022","unstructured":"Bratkovic D, Margvelashvili L, Tchan MC, Nisbet J, Smith N (2022) PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study. Metabolism 128:155116. https:\/\/doi.org\/10.1016\/j.metabol.2021.155116","journal-title":"Metabolism"},{"issue":"10460","key":"9948_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0140-6736(24)01556-3","volume":"404","author":"ACL Muntau","year":"2024","unstructured":"Muntau ACL, Ezgu N, Schwartz F, Lah IVD, Bratkovic M, Margvelashvili D, Kiykim L, Zori E, Campistol R, Plana J (2024) Effects of oral sepiapterin on blood phenylalanine levels in a broad range of patients with phenylketonuria: results of a phase 3, randomised, double-blind, placebocontrolled trial (APHENITY). Lancet 404(10460):1333\u20131345","journal-title":"Lancet"},{"issue":"4","key":"9948_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ymgme.2012.10.006","volume":"107","author":"JC Rocha","year":"2012","unstructured":"Rocha JC, van Spronsen FJ, Almeida MF, Soares G, Quelhas D, Ramos E, Guimaraes JT, Borges N (2012) Dietary treatment in phenylketonuria does not lead to increased risk of obesity or metabolic syndrome. Mol Genet Metab 107(4):659\u2013663. https:\/\/doi.org\/10.1016\/j.ymgme.2012.10.006","journal-title":"Mol Genet Metab"},{"key":"9948_CR15","unstructured":"FDA (2022) Guidance for Industry: assessing the effects of Food on drugs in INDs and NDAs \u2014 clinical pharmacology considerations. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations"},{"issue":"3","key":"9948_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10928-017-9565-6","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, Mehrotra D, Riley S, Sager P, Tornoe C, Wang Y (2018) Correction to: scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45(3):399. https:\/\/doi.org\/10.1007\/s10928-017-9565-6","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9948_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ph17111411","volume-title":"A phase 1 study to assess the Pharmacokinetics, Food Effect, Safety, and tolerability of sepiapterin in healthy Japanese and non-japanese participants","author":"L Gao","year":"2024","unstructured":"Gao L, Kaushik D, Ingalls K, Smith N, Kong R (2024) A phase 1 study to assess the Pharmacokinetics, Food Effect, Safety, and tolerability of sepiapterin in healthy Japanese and non-japanese participants. Pharmaceuticals, Accepted"},{"key":"9948_CR18","unstructured":"FDA (2017) Guidance for Industry E14: Clinical Evaluation of QT\/QTc interval Prolongation for Non-Antiarrhythmic Drugs-Questions and Answers (R3). doi:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-1"},{"issue":"3","key":"9948_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10928-017-9565-6","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, Fergber G, Huang d, Liu J, Riley DM, Sager S, Tornoe P, Wang C Y (2018) Correction to: scientific White Paper on Concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45(3):399","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9948_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bcp.13128","volume":"83","author":"J Taubel","year":"2017","unstructured":"Taubel J, Ferber G, Fox G, Fernandes S, Lorch U, Camm AJ (2017) Thorough QT study of the effect of intravenous amisulpride on QTc interval in caucasian and Japanese healthy subjects. Br J Clin Pharmacol 83(2):339\u2013348. https:\/\/doi.org\/10.1111\/bcp.13128","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"9948_CR21","doi-asserted-by":"publisher","first-page":"e0136369","DOI":"10.1371\/journal.pone.0136369","volume":"10","author":"J Taubel","year":"2015","unstructured":"Taubel J, Ferber G, Lorch U, Wang D, Sust M, Camm AJ (2015) Single doses up to 800\u00a0mg of E-52862 do not prolong the QTc Interval\u2013A retrospective validation by pharmacokinetic-pharmacodynamic modelling of Electrocardiography Data utilising the effects of a meal on QTc to demonstrate ECG assay sensitivity. PLoS ONE 10(8):e0136369. https:\/\/doi.org\/10.1371\/journal.pone.0136369","journal-title":"PLoS ONE"},{"issue":"2","key":"9948_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1365-2125.2012.04376.x","volume":"75","author":"J Taubel","year":"2013","unstructured":"Taubel J, Lorch U, Ferber G, Singh J, Batchvarov VN, Savelieva I, Camm AJ (2013) Insulin at normal physiological levels does not prolong QT(c) interval in thorough QT studies performed in healthy volunteers. Br J Clin Pharmacol 75(2):392\u2013403. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04376.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9948_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","volume":"159","author":"CE Pollard","year":"2017","unstructured":"Pollard CE, Skinner M, Lazic SE, Prior HM, Conlon KM, Valentin JP, Dota C (2017) An analysis of the relationship between preclinical and clinical QT interval-related data. Toxicol Sci 159(1):94\u2013101. https:\/\/doi.org\/10.1093\/toxsci\/kfx125","journal-title":"Toxicol Sci"},{"issue":"1","key":"9948_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s0008-6363(02)00846-5","volume":"58","author":"WS Redfern","year":"2003","unstructured":"Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58(1):32\u201345. https:\/\/doi.org\/10.1016\/s0008-6363(02)00846-5","journal-title":"Cardiovasc Res"},{"issue":"1","key":"9948_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1476-5381.2009.00395.x","volume":"159","author":"RM Wallis","year":"2010","unstructured":"Wallis RM (2010) Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br J Pharmacol 159(1):115\u2013121. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00395.x","journal-title":"Br J Pharmacol"},{"issue":"9","key":"9948_CR26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s40261-017-0547-7","volume":"37","author":"H Olsson","year":"2017","unstructured":"Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L (2017) Effect of Degarelix, a Gonadotropin-releasing hormone receptor antagonist for the treatment of prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and active Comparator Controlled Thorough QT\/QTc Trial in Healthy men. Clin Drug Investig 37(9):873\u2013879. https:\/\/doi.org\/10.1007\/s40261-017-0547-7","journal-title":"Clin Drug Investig"},{"issue":"5","key":"9948_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11306-022-01885-9","volume":"18","author":"L Rasmussen","year":"2022","unstructured":"Rasmussen L, Foulks Z, Wu J, Burton C, Shi H (2022) Establishing pteridine metabolism in a progressive isogenic breast cancer cell model - part II. Metabolomics 18(5):27. https:\/\/doi.org\/10.1007\/s11306-022-01885-9","journal-title":"Metabolomics"},{"issue":"6","key":"9948_CR28","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1073\/pnas.80.6.1546","volume":"80","author":"CA Nichol","year":"1983","unstructured":"Nichol CA, Lee CL, Edelstein MP, Chao JY, Duch DS (1983) Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. Proc Natl Acad Sci U S A 80(6):1546\u20131550. https:\/\/doi.org\/10.1073\/pnas.80.6.1546","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9948_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1042\/BJ20110293","volume":"438","author":"ER Werner","year":"2011","unstructured":"Werner ER, Blau N, Thony B (2011) Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 438(3):397\u2013414. https:\/\/doi.org\/10.1042\/BJ20110293","journal-title":"Biochem J"},{"key":"9948_CR30","unstructured":"FDA (2020) Guidance for Industry: Safety Testing of Drug metabolites. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-testing-drug-metabolites"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09948-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-024-09948-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09948-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T22:05:38Z","timestamp":1739657138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-024-09948-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9948"],"URL":"https:\/\/doi.org\/10.1007\/s10928-024-09948-1","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"14 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LG, YH, NS, and RK are employees of PTC Therapeutics, Inc and may own stocks in PTC Therapeutics. AU, NG, and TP are employees of Certara, Certara received funds from PTC Therapeutics to conduct research on sepiapterin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}